Losartan Overdose and Accidental Excess Dose: Recognition, Treatment, and Clinical Management

How Losartan Works: Mechanism Behind Overdose Effects

Losartan is a selective, competitive antagonist of the angiotensin II type 1 (AT1) receptor. It blocks the binding of angiotensin II, a potent vasoconstrictor, preventing aldosterone secretion, sympathetic activation, and vascular smooth muscle contraction. This mechanism explains why excess dosing primarily manifests as an exaggerated drop in blood pressure.

The parent compound undergoes extensive first-pass hepatic metabolism via cytochrome P450 enzymes (primarily CYP2C9 and CYP3A4) to produce EXP-3174, an active carboxylate metabolite that is 10 to 40 times more potent than losartan itself at blocking the AT1 receptor 1. This metabolite accounts for most of the drug's pharmacologic activity. Losartan's oral bioavailability is roughly 33%, and both the parent drug and EXP-3174 are approximately 99% bound to plasma proteins, predominantly albumin 2. Peak plasma concentrations of losartan occur within one hour, while EXP-3174 peaks at three to four hours.

Unlike ACE inhibitors, losartan does not inhibit bradykinin degradation. This distinction matters in overdose scenarios because bradykinin-mediated effects (severe angioedema, refractory hypotension from kinin potentiation) are far less likely with ARB excess than with ACE inhibitor excess 3. The AT1 selectivity also means that AT2 receptor-mediated pathways (vasodilation, anti-proliferation) remain active during overdose, which may partially offset extreme vasoconstriction collapse.

Recognizing Losartan Overdose: Symptoms and Clinical Presentation

The most reliable indicator of losartan overdose is symptomatic hypotension. Patients may present with dizziness, lightheadedness, syncope, or frank cardiovascular collapse depending on the dose ingested and underlying comorbidities.

According to the FDA-approved prescribing information, limited data exist on human overdose with losartan 2. The most likely manifestations are hypotension and tachycardia. Bradycardia could occur from parasympathetic stimulation but is reported less frequently. Post-marketing surveillance and poison center data support a generally favorable toxicity profile for isolated ARB ingestions 4.

A retrospective analysis of ARB exposures reported to U.S. poison control centers found that the majority of single-agent ARB ingestions resulted in minimal clinical effects. Among 4,514 single-substance ARB exposures analyzed, 78.3% experienced no or minor effects, and fatalities from isolated ARB ingestion were exceedingly rare 4. Severe outcomes were almost exclusively associated with co-ingestants such as beta-blockers, calcium channel blockers, or other antihypertensives.

Expected clinical features by system include:

Cardiovascular: Hypotension (systolic blood pressure <90 mmHg), orthostatic dizziness, reflex tachycardia, and rarely bradycardia.

Renal: Acute kidney injury from prolonged hypoperfusion, hyperkalemia from reduced aldosterone secretion, particularly in patients already taking potassium-sparing diuretics or potassium supplements.

Neurologic: Dizziness, confusion, or altered mental status secondary to cerebral hypoperfusion rather than direct neurotoxicity.

Metabolic: Hyponatremia and hyperkalemia are possible, especially in patients with pre-existing renal impairment or those taking concomitant medications that raise potassium.

Emergency Treatment Protocol for Losartan Overdose

Supportive care is the cornerstone. No specific antidote exists for losartan or any ARB.

The initial management follows standard toxicologic principles. Secure the airway, breathing, and circulation. Place the patient in a supine or Trendelenburg position to optimize venous return. Establish IV access and begin isotonic crystalloid resuscitation (normal saline or lactated Ringer's) for hypotension 5.

Gastrointestinal decontamination: Activated charcoal (1 g/kg, maximum 50 g in adults) should be considered if the patient presents within one to two hours of ingestion, the airway is protected, and no contraindications exist. The American Academy of Clinical Toxicology and the European Association of Poisons Centres and Clinical Toxicologists recommend single-dose activated charcoal only when it can be administered within this window and the ingestion is potentially toxic 6. Gastric lavage is generally not recommended for ARB ingestion given the relatively benign toxicity profile.

Vasopressor support: If IV fluids fail to restore adequate blood pressure, vasopressors should be initiated. Norepinephrine is the first-line agent for vasodilatory hypotension. The Surviving Sepsis Campaign guidelines, while designed for sepsis, provide a useful framework: start norepinephrine at 0.1 to 0.5 mcg/kg/min and titrate to a mean arterial pressure of 65 mmHg or higher 7. Vasopressin may be added as a second-line agent.

Electrolyte monitoring: Check serum potassium, sodium, creatinine, and blood urea nitrogen at presentation and every four to six hours. Hyperkalemia (potassium >5.5 mEq/L) warrants treatment with calcium gluconate for cardiac membrane stabilization, insulin plus dextrose, and sodium polystyrene sulfonate or patiromer if refractory.

The Role of Hemodialysis in Losartan Overdose

Hemodialysis does not effectively clear losartan or EXP-3174. Both compounds are approximately 99% protein-bound, leaving very little free drug available for removal across a dialysis membrane.

The FDA prescribing information explicitly states that neither losartan nor its active metabolite can be removed by hemodialysis 2. This contrasts with certain other antihypertensive overdoses (atenolol, for instance, has low protein binding at 6 to 16% and can be partially cleared by dialysis). The high protein binding and hepatic metabolism of losartan make extracorporeal removal impractical.

The Extracorporeal Treatments in Poisoning (EXTRIP) workgroup has not issued specific recommendations for ARB overdose, but the pharmacokinetic profile alone (large volume of distribution of approximately 34 liters, high protein binding) argues against dialysis as a treatment modality 8. Dialysis should only be considered if co-ingestants are present that are dialyzable (lithium, methanol, ethylene glycol, salicylates) or if renal replacement therapy is needed for refractory hyperkalemia or volume overload.

Accidental Double Doses and Therapeutic Excess

Taking two 50 mg or 100 mg tablets accidentally represents the most common "overdose" scenario in clinical practice. Single extra-dose events rarely cause more than mild, transient hypotension.

The maximum recommended daily dose for losartan is 100 mg for hypertension and 150 mg (given as 50 mg three times daily in some heart failure protocols, though this is off-label) 2. An accidental double dose (200 mg in a patient prescribed 100 mg) falls within a range that has been studied in clinical trials without catastrophic effects. In phase I dose-ranging studies, healthy volunteers tolerated single doses up to 150 mg with proportional blood pressure reductions and no serious adverse events 9.

Practical steps for an accidental double dose:

1. Do not take the next scheduled dose. Skip it entirely.
2. Check blood pressure if a home monitor is available. Seek medical attention if systolic pressure drops below 90 mmHg or if dizziness, fainting, or palpitations develop.
3. Stay hydrated. Drink water but avoid alcohol, which compounds the hypotensive effect.
4. Resume the normal dosing schedule the following day.
5. Call Poison Control (1-800-222-1222) if uncertain about the amount ingested or if symptoms develop.

Patients on concurrent antihypertensives, diuretics, or those with chronic kidney disease face higher risk from even modest dosing errors. A patient taking losartan 100 mg, hydrochlorothiazide 25 mg, and amlodipine 10 mg who accidentally doubles only the losartan may still experience clinically significant hypotension because of the additive vasodilatory burden.

Pediatric Considerations in Losartan Overdose

Children are more vulnerable to the hypotensive effects of ARB ingestion per kilogram of body weight. Any suspected pediatric losartan ingestion warrants a call to Poison Control and, in most cases, emergency department evaluation.

Losartan is FDA-approved for hypertension in children aged 6 and older at doses of 0.7 mg/kg (up to 50 mg) once daily 2. A toddler who ingests a parent's 100 mg tablet could receive several times the weight-adjusted therapeutic dose. Data from the National Poison Data System indicate that exploratory ingestions of single ARB tablets in children under 6 rarely produce severe symptoms, but blood pressure monitoring for at least four to six hours is recommended 10.

The American Association of Poison Control Centers recommends emergency department referral for any child under 6 who ingests more than one ARB tablet, any child who is symptomatic after ingestion, or any adolescent with intentional overdose 10. Activated charcoal dosing in pediatrics is 0.5 to 1 g/kg (maximum 50 g), and the same one-to-two-hour window applies.

Drug Interactions That Amplify Overdose Risk

Certain co-administered medications transform what might otherwise be a mild losartan overdose into a dangerous one. The most clinically significant interactions involve drugs that lower blood pressure, raise potassium, or alter losartan metabolism.

Potassium-elevating agents: Spironolactone, eplerenone, amiloride, triamterene, trimethoprim, and potassium supplements all increase the risk of life-threatening hyperkalemia when combined with excess losartan. The RALES trial demonstrated that spironolactone plus an ACE inhibitor increased hyperkalemia-related hospitalizations and deaths; the same logic applies to ARBs 11.

NSAIDs: Ibuprofen, naproxen, and other NSAIDs blunt the antihypertensive effect of losartan at therapeutic doses but simultaneously impair renal blood flow. In overdose, the combination may produce acute kidney injury more readily than either agent alone 12.

CYP2C9 inhibitors: Fluconazole, amiodarone, and fluvoxamine inhibit the conversion of losartan to EXP-3174. This paradoxically may reduce the intensity of overdose effects from the active metabolite, but prolongs exposure to the parent compound 1.

Dual RAAS blockade: Combining losartan with an ACE inhibitor (e.g., lisinopril) or a direct renin inhibitor (aliskiren) at any dose amplifies the risk of hypotension, hyperkalemia, and renal failure. The ONTARGET trial (N=25,620) showed that telmisartan plus ramipril increased adverse renal outcomes compared to either agent alone without added cardiovascular benefit 13. This finding, as noted by the 2017 ACC/AHA hypertension guideline, led to a class-wide recommendation against dual RAAS blockade except in specific heart failure populations under close monitoring 14.

Monitoring Timeline and Disposition

Asymptomatic patients who ingested a known amount of losartan alone can generally be observed for four to six hours. If blood pressure and heart rate remain stable, serum potassium is normal, and renal function is preserved, discharge with close follow-up is appropriate.

Patients who are symptomatic, took a large intentional overdose, or co-ingested other medications should be admitted for a minimum of 12 to 24 hours of continuous monitoring. The active metabolite EXP-3174 has a half-life of 6 to 9 hours, meaning peak pharmacologic effects from an acute overdose may not manifest for three to four hours and could persist for 24 to 36 hours 2.

Laboratory monitoring during observation should include:

• Basic metabolic panel (potassium, sodium, creatinine, BUN, glucose) at 0, 4, and 8 hours
• Continuous telemetry for arrhythmia detection (hyperkalemia can cause peaked T waves, widened QRS, and ventricular fibrillation)
• Urine output monitoring (target >0.5 mL/kg/hr)
• ECG at presentation and with any potassium value >5.5 mEq/L

Losartan's Safety Profile in Context: LIFE Trial and Therapeutic Index

The LIFE trial (Losartan Intervention For Endpoint reduction in hypertension, N=9,193) established losartan's cardiovascular safety over a mean 4.8 years of follow-up. Losartan 50 to 100 mg daily produced a 13% relative risk reduction in the composite endpoint of cardiovascular death, stroke, and myocardial infarction compared to atenolol (adjusted p=0.021) 15. Adverse event rates in the losartan arm were lower than in the atenolol arm, with fewer patients discontinuing therapy due to side effects (9.4% vs. 14.5%).

This long-term safety data, combined with the poison control analyses showing low fatality rates from isolated ARB ingestion, supports the characterization of losartan as having a relatively wide therapeutic index 4. A 2013 review in Clinical Toxicology found zero deaths attributable to isolated ARB ingestion among over 8,000 exposures reported to U.S. poison centers between 2000 and 2012.

The wide safety margin does not eliminate risk. Patients with heart failure, severe aortic or mitral stenosis, bilateral renal artery stenosis, or volume depletion from diuretics or vomiting are substantially more vulnerable to the hemodynamic consequences of even modest overdose 2.

When to Call 911 vs. Poison Control

Call 911 immediately if the patient is unconscious, has a seizure, cannot stand due to dizziness, has a heart rate above 130 bpm or below 50 bpm, or has systolic blood pressure below 80 mmHg. Call Poison Control at 1-800-222-1222 for all other ingestion scenarios, including accidental double doses in stable patients, exploratory ingestions in children who appear well, and uncertain dose situations where the patient is asymptomatic.